Abeona Therapeutics (NASDAQ:ABEO) CFO Sells $48,698.65 in Stock

Key Points

• Joseph Walter Vazzano, CFO of Abeona Therapeutics, recently sold 9,035 shares for approximately $48,698.65, reducing his ownership by 1.95% to 453,631 shares valued at about $2.45 million.
• Abeona Therapeutics reported a beating EPS of $1.71 for the last quarter, significantly surpassing the consensus estimate of a loss of $0.39, but revenue was notably low at $0.40 million against an expectation of $21.71 million.
• The company's stock holds a consensus "Buy" rating among analysts, with target prices ranging from $19.00 to $20.00, reflecting positive sentiment despite recent stock performance challenges.

Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) CFO Joseph Walter Vazzano sold 9,035 shares of the business's stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $5.39, for a total transaction of $48,698.65. Following the transaction, the chief financial officer owned 453,631 shares of the company's stock, valued at approximately $2,445,071.09. This trade represents a 1.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Joseph Walter Vazzano also recently made the following trade(s):

• On Tuesday, July 22nd, Joseph Walter Vazzano sold 1,502 shares of Abeona Therapeutics stock. The stock was sold at an average price of $6.64, for a total transaction of $9,973.28.
• On Wednesday, July 9th, Joseph Walter Vazzano sold 25,411 shares of Abeona Therapeutics stock. The stock was sold at an average price of $5.86, for a total transaction of $148,908.46.

Abeona Therapeutics Price Performance

Shares of NASDAQ ABEO remained flat at $5.28 during trading hours on Wednesday. 996,147 shares of the company traded hands, compared to its average volume of 1,001,008. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.65 and a current ratio of 6.73. The firm has a market capitalization of $270.75 million, a P/E ratio of 7.54 and a beta of 1.67. The firm's 50 day simple moving average is $6.44 and its two-hundred day simple moving average is $5.93. Abeona Therapeutics Inc. has a 1 year low of $3.93 and a 1 year high of $7.54.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported $1.71 EPS for the quarter, topping the consensus estimate of ($0.39) by $2.10. The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $21.71 million. As a group, equities analysts anticipate that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current fiscal year.

Institutional Trading of Abeona Therapeutics

Several large investors have recently made changes to their positions in ABEO. Bank of America Corp DE boosted its holdings in shares of Abeona Therapeutics by 16.7% in the 4th quarter. Bank of America Corp DE now owns 264,439 shares of the biopharmaceutical company's stock valued at $1,473,000 after acquiring an additional 37,774 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of Abeona Therapeutics in the 4th quarter valued at $67,000. Wellington Management Group LLP acquired a new position in shares of Abeona Therapeutics in the 4th quarter valued at $520,000. Cannon Global Investment Management LLC acquired a new position in shares of Abeona Therapeutics in the 1st quarter valued at $67,000. Finally, OMERS ADMINISTRATION Corp lifted its stake in shares of Abeona Therapeutics by 11.0% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 72,200 shares of the biopharmaceutical company's stock valued at $344,000 after purchasing an additional 7,155 shares during the period. 80.56% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ABEO has been the topic of several research analyst reports. HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of Abeona Therapeutics in a research report on Monday, August 18th. Oppenheimer boosted their target price on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the stock an "outperform" rating in a research report on Friday, August 15th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, Abeona Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $19.50.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.